Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566813 · ClinicalTrials.gov registry record · Phase 1
Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00566813 is a Phase 1 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 10 participants.
The verdict
NCT00566813, a Phase 1 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary purpose of this study is to demonstrate the safety of allogeneic islet transplantation in type 1 diabetic patients performed at the University of Illinois at Chicago (UIC). The purpose is to reproduce the Edmonton protocol to demonstrate that pancreatic islets isolated at UIC are safe and of sufficient quality to provide reproducible graft function.
Interventions
- DRUG Islet Cell Transplant
- DRUG Islet Cell Transplant plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2004-11 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00566813
The ClinicalTrials.gov registry entry for NCT00566813 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Islet Cell Transplant is the first listed.
NCT00566813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00566813 about?
NCT00566813 is a clinical study titled "Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression". The primary purpose of this study is to demonstrate the safety of allogeneic islet transplantation in type 1 diabetic patients performed at the University of Illinois at Chicago (UIC). The purpose is to reproduce the Edmonton protocol to demonstrate that pancreatic islets isolated at UIC are safe an...
What is the current status of trial NCT00566813?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2004-11. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT00566813?
The interventions under investigation include: Islet Cell Transplant (DRUG), Islet Cell Transplant plus (DRUG).
Who is sponsoring clinical trial NCT00566813?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.